Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29176234 | 0.88 | CHRNB2 (0.40) | ADKCHRNB2CHRNA4 | |
| SCHEMBL30811810 | 0.88 | CHRNB2 (0.40) | ADKCHRNB2CHRNA4 | |
| SCHEMBL29107985 | 0.88 | CHRNB2 (0.40) | ADKCHRNB2CHRNA4 | |
| SCHEMBL29108017 | 0.86 | CHRNB2 (0.39) | ADKCHRNB2CHRNA4 | |
| SCHEMBL14299573 | 0.85 | CHEK1 (0.40) | ADKNOS3NOS1FGFR1KDR | |
| SCHEMBL30811822 | 0.81 | CHRNB2 (0.37) | ADKCHRNB2CHRNA4 | |
| SCHEMBL14299566 | 0.81 | ADK (0.34) | ADKCHRNB2CHRNA4FGFR1KDR | |
| SCHEMBL14299571 | 0.81 | KDM4E (0.39) | ADKKDM4EPIK3CACHRNB2CHRNA4 | |
| SCHEMBL14299554 | 0.81 | CHRNA7 (0.41) | ADKKDM4EFGFR1SMN1; SMN2KDR | |
| SCHEMBL14299578 | 0.80 | TRPV6 (0.40) | ADKPIK3CACHRNB2CHRNA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290507-B2 | B-RAF kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-9290507-B2 | B-RAF kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-8865703-B2 | Pyridyltriazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865703-B2 | Pyridyltriazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | CDK2, TNNI3K, CDK1 | ADK 560/4885NOS3 1771/4885NOS1 1598/4885 |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | CCNT1, CCNT2, MKI67 | ADK 3744/4885NOS3 523/4885NOS1 444/4885 |
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | ADK 634/4885NOS3 2489/4885NOS1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.